(NYSE: PEN) Penumbra's forecast annual revenue growth rate of 12.59% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 5.7%, and it is also forecast to beat the US market's average forecast revenue growth rate of 6.55%.
Penumbra's revenue in 2023 is $995,059,000.On average, 7 Wall Street analysts forecast PEN's revenue for 2023 to be $40,956,379,395, with the lowest PEN revenue forecast at $40,834,955,228, and the highest PEN revenue forecast at $41,031,140,556. On average, 7 Wall Street analysts forecast PEN's revenue for 2024 to be $48,924,290,385, with the lowest PEN revenue forecast at $47,389,274,313, and the highest PEN revenue forecast at $49,673,523,042.
In 2025, PEN is forecast to generate $56,183,417,710 in revenue, with the lowest revenue forecast at $53,754,008,048 and the highest revenue forecast at $56,916,710,067.